Kintara Therapeutics Inc (NASDAQ:KTRA) shares are trading lower by 36% to $0.49 Wednesday afternoon and lower by 87% since Tuesday's open. The company has decided to stop developing their drug VAL-083 for glioblastoma because it didn't show better results than current treatments.
Kintara is now concentrating on REM-001, a localized tumor treatment, and looking into ways to enhance shareholder value through strategic options.
See Also: Why Sunrun (RUN) Stock Is Moving
What Else?
Preliminary study results for VAL-083 were disappointing, but the company says more data will be available in 2024 for further evaluation. They are planning to start a study for REM-001 in cutaneous metastatic breast cancer by the end of 2023, supported by a $2 million NIH grant.
Meanwhile, REM-001, a photodynamic therapy, has shown promise in previous trials, with an impressive 80% complete response rate in cutaneous metastatic breast cancer.
According to data from Benzinga Pro, KTRA has a 52-week high of $15.50 and a 52-week low of $0.48.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
